Disc Medicine with their Phase 1 and 2s and recent EPP trial...

Disc Medicine with their Phase 1 and 2s and recent EPP trial flunk up another 0.6% last night, still holding at equivalent ~$24 CUV share price with market cap $1.2 Billion AUD. The cash burning Disc market cap is about $450 Million greater than CUV who is running a Phase 3 blockbuster, printing cash, enjoying a monopoly in EPP for many year to come and apparently with a tanning/protective product only a couple of years away? Clinuvel also have three Investor Relations Experts in three continents so lets see how things went last night:

UR9.F in Europe 300 shares traded.
CLVLY depository receipts in US 325 shares traded.
And CUV today as usual manipulated down again on tiny volume as per last 5 years since hedge fund started shorting CUV.

By way of comparison, Disc last night 200 thousand shares traded, equivalent to about $10 M AUD. Not sure if they have three IR Experts, but Clinuvel could certainly learn a lot from them on how to attract shareholder interest and drive value for shareholders. CUV is definitely a more exciting and advanced company but struggling to attract investment from what I am observing. Amazingly Clinuvel even in the position to run a share buyback which they have stated they will do for 1.5 Million shares (out of just 50 Million shares on issue) so this in itself would set them apart from high risk Disc from an investment viewpoint you would think. Looking forward to when they can just get 10, 20 or 50 thousand genuine shares traded in Europe or the States.

All IMO DYOR